(Total Views: 466)
Posted On: 10/28/2018 10:49:58 AM
Post# of 212
$INSY Another week that ended on a bad note. Share price took another tumble. The drop in price may reflect an article that was written by an investment consultant. The gist of the article is that Insys Therapeutics will continue to suffer losses that will leave the company broke. The justification for the interpretation rests with the on going opium indictments/trials/settlements and future court cases within the medical industry.
The article strongly suggests that INSYS will not be able use the Medical (synthetic) Marijuana to offset the Fentanyl revenues that have been lost and will continue to be lost. According to the author of the article, there will not be enough cash reserves to pay off any additional settlements.
The article does have some merit. What may be lacking in its analysis and conclusion is an understanding of the new Sales Markets in the World that Insys Therapeutics has entered and the areas of product development that have not been made available to the public. R&D has inherent risks. One of the greatest risks that a company takes is that a potentially viable and extremely lucrative product is announced and OTHER companies jump on the bandwagon and quickly dilute the Market.
I do not know what products Insys may be developing and keeping under wraps BUT the New Leadership has shown itself to be quite adept at bringing new products to and beyond the clinical test stage. I believe the future holds a wealth of new products that will get INSYS Therapeutics through the current Bad Times.
The statement above is strictly MY OPINION. I am a shareholder. I do NOT receive any payment, gifts, special favors from Insys Therapeutics or any individuals or companies employed by Insys Therapeurics. I like this stock and my comments reflect my belief that the company is a good investment for me now and its value will increase in the future. Again, the wording is MY OPINION. Please complete your own due diligence if you are considering investing in this company.
The article strongly suggests that INSYS will not be able use the Medical (synthetic) Marijuana to offset the Fentanyl revenues that have been lost and will continue to be lost. According to the author of the article, there will not be enough cash reserves to pay off any additional settlements.
The article does have some merit. What may be lacking in its analysis and conclusion is an understanding of the new Sales Markets in the World that Insys Therapeutics has entered and the areas of product development that have not been made available to the public. R&D has inherent risks. One of the greatest risks that a company takes is that a potentially viable and extremely lucrative product is announced and OTHER companies jump on the bandwagon and quickly dilute the Market.
I do not know what products Insys may be developing and keeping under wraps BUT the New Leadership has shown itself to be quite adept at bringing new products to and beyond the clinical test stage. I believe the future holds a wealth of new products that will get INSYS Therapeutics through the current Bad Times.
The statement above is strictly MY OPINION. I am a shareholder. I do NOT receive any payment, gifts, special favors from Insys Therapeutics or any individuals or companies employed by Insys Therapeurics. I like this stock and my comments reflect my belief that the company is a good investment for me now and its value will increase in the future. Again, the wording is MY OPINION. Please complete your own due diligence if you are considering investing in this company.
(0)
(0)Scroll down for more posts ▼
